# Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients

Study · id `cardio:ct-nct06759272` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06759272](<https://clinicaltrials.gov/study/NCT06759272>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06759272

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06759272. Randomized; single masking; primary purpose health services research. Start 2025-02 (anticipated); primary completion 2026-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose health services research
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06759272, source copy `cardio:ctgov-nct06759272-2025-01-07`, retrieved 2026-10-31)
- Planned start: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06759272, source copy `cardio:ctgov-nct06759272-2025-01-07`, retrieved 2026-10-31)
- Primary completion: 2026-02 (anticipated) (ClinicalTrials.gov record NCT06759272, source copy `cardio:ctgov-nct06759272-2025-01-07`, retrieved 2026-10-31)
- Completion: 2026-02 (anticipated) (ClinicalTrials.gov record NCT06759272, source copy `cardio:ctgov-nct06759272-2025-01-07`, retrieved 2026-10-31)
- Countries: Malaysia (ClinicalTrials.gov record NCT06759272, source copy `cardio:ctgov-nct06759272-2025-01-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06759272-2025-01-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
- Condition: Coronary Arterial Disease (CAD)
- Condition: ACS (Acute Coronary Syndrome)
- Condition: SCAD
- Intervention (Genetic): CYP2C19 genotype-guided antiplatelet therapy
- Lead sponsor: Nur Hafizah Annezah binti Utuh
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)

## Provenance

Content hash: 730473f0f93e9047277b2549173a55b8ab7db2b761d8ad5c099e4d2b0fe1dbac
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
